Response to Comments: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

This response-to-comments policy states that coverage decisions for amniotic and placental-derived product injections/applications for non-wound musculoskeletal indications will be grounded in the best available published clinical evidence (peer-reviewed studies, systematic reviews, meta-analyses, consensus statements, and guidelines) per CMS Program Integrity Manual Chapter 13. Anecdotal or unpublished non-peer-reviewed information is given limited weight, and MACs may consolidate or redact portions of public comments submitted during the comment period.

"Anecdotal or unpublished non-peer-reviewed information has limited influence and is not sufficient by itself to support coverage determinations."

Sign up to see full coverage criteria, indications, and limitations.